Search

Your search keyword '"Bignon, Y-J"' showing total 316 results

Search Constraints

Start Over You searched for: Author "Bignon, Y-J" Remove constraint Author: "Bignon, Y-J"
316 results on '"Bignon, Y-J"'

Search Results

4. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

5. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

6. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

7. Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition

10. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

11. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers.

12. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

13. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

15. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

18. Hétérogénéité tumorale et échappement métastatique des carcinomes mammaires triples négatifs

19. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

21. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

22. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

29. Oral contraceptive use and breast cancer risk: Retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study.

32. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

33. Polymorphisms in BRCA1 and 17[Beta]-hydroxysteroid dehydrogenase 2 (EDH17B2) genes as modifiers of ovarian cancer risk in carriers of BRCA1 germline mutations

34. Results of the ‘Programme Of Accompanying women after breast Cancer treatment completion in Thermal resorts’ (PACThe) randomised clinical trial of 251 patients

36. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

37. Assessing associations between the AURKAHMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers

38. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

39. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

40. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers

41. Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

42. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort

43. Common BRCA2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA1 Mutation Carriers

46. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

47. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

48. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

49. Abstract P3-14-19: Panitumumab in combination with FEC 100 (5-fluorouracil, epirubicin, cyclophosphamide) followed by docetaxel for operable, triple negative breast cancer (TNBC): Patient outcome

50. Abstract P1-08-34: Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial

Catalog

Books, media, physical & digital resources